Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Tiziana Life Sciences Ltd

Healthcare US TLSA

1.26USD
-0.01(0.79%)

Last update at 2026-06-05T18:16:00Z

Day Range

1.231.28
LowHigh

52 Week Range

0.411.27
LowHigh

Fundamentals

  • Previous Close 1.27
  • Market Cap93.29M
  • Volume51394
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-17.97700M
  • Revenue TTM-3.59500M
  • Revenue Per Share TTM-0.018
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.19

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -15.39700M -26.65700M -30.07346M -10.28741M -9.45843M
Minority interest - - - - 0.00000M
Net income -16.20800M -23.41700M -27.73076M -9.57938M -7.60710M
Selling general administrative 1.63M 0.85M 14.02M 6.21M 4.42M
Selling and marketing expenses - - - - -
Gross profit - 0.00000M 0.00000M 0.00000M 0.00000M
Reconciled depreciation 0.05M 0.14M 0.09M 0.20M 0.01M
Ebit -14.58600M -27.37400M -29.74229M -10.19300M -9.44701M
Ebitda -15.33900M -26.34000M -32.16812M -9.93339M -9.43178M
Depreciation and amortization -0.75300M 1.03M -2.42583M 0.26M 0.02M
Non operating income net other - - - - 0.00000M
Operating income -14.58600M -27.37400M -29.74229M -10.19300M -9.44701M
Other operating expenses 14.59M 27.37M 32.27M 10.19M 9.45M
Interest expense 0.00700M 0.18M 0.34M 0.09M 0.01M
Tax provision 0.00000M -3.24000M -2.20700M -0.54000M -1.53360M
Interest income 0.00000M 0.00000M 0.00800M 0.00100M 0.00900M
Net interest income -0.00700M -0.17600M -0.31200M -0.07200M -0.00946M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 0.81M -3.24000M -2.34270M -0.70803M -1.85133M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 14.59M 27.37M 32.27M 10.19M 9.45M
Cost of revenue - 0.00000M 0.00000M 0.00000M 0.00000M
Total other income expense net -0.81100M 0.72M -0.33117M -0.09440M -0.00946M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -15.39700M -23.41700M -26.13100M -7.30600M -6.29912M
Net income applicable to common shares -15.39700M -23.41700M -26.13100M -9.32300M -7.93400M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 12.18M 26.48M 48.83M 70.55M 2.37M
Intangible assets - - 0.13M 0.10M -
Earning assets - - - - -
Other current assets - 6.16M 6.49M 0.00200M 1.30M
Total liab 6.65M 6.91M 7.55M 8.25M 7.85M
Total stockholder equity 5.54M 19.57M 41.28M 62.29M -5.48067M
Deferred long term liab - - - - -
Other current liab 0.01M 1.58M 3.14M 0.08M 0.08M
Common stock 0.10M 0.10M 0.10M 7.96M 5.37M
Capital stock 0.10M 0.10M 0.10M 7.96M 5.37M
Retained earnings -133.67600M -116.26300M -108.06300M -84.92171M -56.57156M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.12M 0.43M
Cash 1.18M 18.12M 42.19M 65.71M 0.20M
Cash and equivalents - - - - -
Total current liabilities 6.54M 6.66M 7.55M 7.97M 7.31M
Current deferred revenue 2.25M - - 4.25M 0.59M
Net debt -0.93600M -17.75700M -42.18600M -65.15666M 0.62M
Short term debt 0.14M 0.12M - 0.27M 0.28M
Short long term debt - - - - -
Short long term debt total 0.25M 0.36M - 0.55M 0.82M
Other stockholder equity 22.05M 20.16M 30.09M 177.53M 45.72M
Property plant equipment - 0.39M 0.02M 0.36M 0.44M
Total current assets 7.34M 24.28M 48.68M 70.06M 1.50M
Long term investments 4.55M 1.81M - - -
Net tangible assets - 19.57M 41.15M 62.39M -5.51400M
Short term investments - - - - -
Net receivables 6.05M 5.99M 5.31M 3.78M 1.28M
Long term debt - - - - -
Inventory - -5.99000M -5.30700M 0.56M -
Accounts payable 4.14M 4.96M 4.41M 3.36M 6.36M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 117.06M 115.57M 119.15M -38.27494M -0.03500M
Additional paid in capital - - - - -
Common stock total equity - - - 10.79M 4.10M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.13M 0.12M 0.43M
Deferred long term asset charges - - - - -
Non current assets total 4.85M 2.19M 0.15M 0.49M 0.87M
Capital lease obligations 0.25M 0.36M 0.00000M 0.56M 0.62M
Long term debt total - - - - 0.41M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -3.99600M 0.13M -0.12300M -0.00300M 0.00000M
Change to liabilities -1.35500M -0.68500M 1.15M 0.44M 0.14M
Total cashflows from investing activities -2.67600M 0.13M -0.12300M -0.00400M -0.00400M
Net borrowings -0.05500M -0.15200M -0.11400M 1.68M 1.68M
Total cash from financing activities -0.05500M -0.02300M 78.31M 1.73M 9.55M
Change to operating activities 1.35M -0.77300M -1.40900M 0.14M 1.80M
Net income -15.39700M -26.65700M -30.07346M -10.28741M -9.45843M
Change in cash -24.06400M -23.63800M 65.50M -5.26040M 5.22M
Begin period cash flow 42.19M 65.82M 0.21M 5.46M 0.06M
End period cash flow 18.12M 42.19M 65.71M 0.20M 5.28M
Total cash from operating activities -19.61500M -21.76200M -12.67018M -6.98196M -4.33078M
Issuance of capital stock 0.00000M 0.00000M 82.71M 1.93M 11.43M
Depreciation 0.05M 0.14M 0.10M 0.26M 0.02M
Other cashflows from investing activities - 0.15M 0.15M 0.15M 0.15M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables -1.15800M -0.08800M -0.03100M -0.28700M -1.54270M
Sale purchase of stock - - - 1.47M 8.57M
Other cashflows from financing activities -3.99600M 0.13M 0.54M -0.20585M -1.31839M
Change to netincome -3.10500M 2.29M 15.00M 1.99M 1.37M
Capital expenditures 0.00000M 0.02M 0.13M 0.00393M 0.00400M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -1.16400M -0.77300M -0.31209M 0.30M 1.85M
Stock based compensation -1.41000M 5.17M 5.12M 1.30M 0.80M
Other non cash items -1.69500M 0.87M 14.77M 0.16M 0.08M
Free cash flow -19.61500M -21.78400M -12.80510M -6.98589M -4.33078M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
TLSA
Tiziana Life Sciences Ltd		 -0.01 0.79% 1.26 - - - 3.32 -1.9544
NVO
Novo Nordisk A/S		 -0.475 1.09% 43.27 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 10.61 2.40% 452.35 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 8.07 1.28% 636.80 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Tiziana Life Sciences Ltd

14/15 Conduit Street, London, United Kingdom, W1S 2XJ

Key Executives

Name Title Year Born
Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA Founder, Exec. Chairman & Interim CEO 1972
Dr. Andrea Brancale Scientific Founder NA
Mr. Richard Clarkson Ph.D. Scientific Founder NA
Mr. Andrew Westwell Ph.D. Scientific Founder NA
Ms. Keeren Shah Chief Financial Officer 1977
Dr. Matthew W. Davis M.D., RPh Chief Medical Officer & Acting Chief Scientific Officer NA
Prof. Napoleone Ferrara M.D. Member of Scientific Advisory Board 1957
Prof. Roberto Pellicciari Ph.D. Consultant NA
Mr. Gabriele Marco Antonio Cerrone M.B.A. Founder, Executive Chairman & Interim CEO 1972
Ms. Keeren Shah Chief Financial Officer 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.